Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03078647 · ClinicalTrials.gov registry record · NA
Profound Dermal and SubQ Cartridges for the Treatment of Cellulite
A NA study, sponsored by Syneron Medical.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT03078647: Completed NA study, sponsored by Syneron Medical.
NCT03078647 is a NA study that has completed, run by Syneron Medical. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03078647, a NA study, has completed, sponsored by Syneron Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
Clinical Study to Evaluate the Performance of the Profound System for the Treatment of Cellulite.
Primary Outcome
Evaluate the improvement in global aesthetic appearance of cellulite in treated areas following a single dermal and/or subcutaneous treatment with Profound, as assessed by study investigators at 1,3 and 6 months post treatment visit. Investigators used the following scale: 0=No Change; 1= 1-24% improvement; 2=25-49% improvement; 3=50-74% improvement; 4=75-100% improvement. The analysis calculates the improvement over 25% (grades 2-4)
Interventions
- DEVICE Profound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2019-01-31 |
| Phase | NA |
What the finished NCT03078647 record still lists
NCT03078647 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Profound is the first listed.
NCT03078647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03078647 about?
NCT03078647 is a clinical study titled "Profound Dermal and SubQ Cartridges for the Treatment of Cellulite". Clinical Study to Evaluate the Performance of the Profound System for the Treatment of Cellulite.
What is the current status of trial NCT03078647?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2017-09-13. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT03078647?
The interventions under investigation include: Profound (DEVICE).
Who is sponsoring clinical trial NCT03078647?
This trial is sponsored by Syneron Medical, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03078647's enrollment target sits among peer trials
31 1592nd of 2000 higher than 408 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI